Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Inclusion Criteria: * Participants must have histologically confirmed advanced NSCLC (with a confirmed KRAS mutation via any CLIA-certified method) for which curable treatment modalities are not an option * Part I Dose Escalation: Participants are required to have measurable disease per RECIST 1.1 within 4 weeks of study entry * MTD Expansion and Part II: Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 20 mm with conventional techniques or as \> 10 mm with spiral CT scan. See section 10 for the evaluation of measureable disease. * Age ≥ 18 years. Because no dosing or adverse event data are currently available in participants \< 18 years of age, children are excluded from this study * Participants are permitted to have any number of prior therapies prior to enrollment * ECOG performance status \< 2 (see Appendix A). * Participants must have normal organ and marrow function as defined below: * Absolute neutrophil count \> 1,500mm3 * Hemoglobin \> 9 g/dL * Platelets \> 100,000/mcL * Total bilirubin \< 2 X institutional upper limit of normal (ULN) * AST (SGOT)/ALT (SGPT) \< 2.5 X ULN -OR- * AST (SGOT)/ALT (SGPT) \< 5.0 X ULN if hepatic metastases are present * Creatinine \< 1.5 X the institutional ULN -OR- * Calculated creatinine clearance (determined as per Cockcroft-Gault) \> 50 mL/min * The effects of palbociclib and binimetinib on the d…